Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
Abstract Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), which lead to early death due to progressive lung disease. The development of small-molecule modulators that directly interact with CFTR to aid in protein folding (“correctors”) an...
Enregistré dans:
Auteurs principaux: | , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ada0900b04f2474491bb981f326adf27 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|